A new GLP-1 opportunity for pharma: Supporting patients’ emotional barriers to weight loss

Despite their remarkable efficacy for many populations, GLP-1s have a relatively low persistence rate over time, due to a combination of factors, including costs, side effects, and, yes, likely even the stigma of being “found out” for being a user.

This is an unacceptable state of affairs, especially as close to 70% of Americans face serious long-term health consequences from being overweight or clinically obese.